EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial

Yasuhiro Matsuda iD, Masaharu Masuda iD, Toshiaki Mano iD, Takuya Tsujimura, Hiroyuki Uematsu, Hirotaka Ooka, Satoshi Kudo iD, Mizuki Ochi iD, Shin Okamoto, Takayuki Ishihara iD, Kiyonori Nanto iD, Yosuke Hata iD und 22 weitere

Europace · 2025

DOI: 10.1093/europace/euaf205 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Yasuhiro Matsuda und 33 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki 660-8511, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation, Glomerular Filtration Rate. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biosense Webster, Inc., Johnson & Johnson MedTech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The SUPPRESS-AF trial showed that pulmonary vein isolation (PVI) plus low-voltage area (LVA) ablation may reduce atrial fibrillation (AF) recurrence in some subgroups. Renal dysfunction is a cause of LVAs due to atrial cardiomyopathy and is also a risk factor for AF recurrence after catheter ablation. The aim of this study was to investigate the efficacy of LVA ablation after PVI stratified by renal function. Methods and results This study was a sub-analysis of the SUPPRESS-AF trial, a multicentre, prospective, randomized, open-label trial. A total of 341 consecutive patients who underwent initial radiofrequency catheter ablation for persistent AF and whose LVAs were ≥5 cm2 were analysed. Patients were randomized to PVI alone (PVI-alone group) or LVA ablation after PVI [PVI + LVA-ablation (ABL) group]. Primary outcome was defined as the recurrence of atrial tachyarrhythmias during the 12 months following ablation. Estimated glomerular filtration rate (eGFR) was assessed before ablation, and patients were stratified by chronic kidney disease (CKD) stage. The mean eGFR was 60 ± 16 mL/min/1.73 m2, and 146 (43%) patients developed the primary outcome. In patients with CKD G1-2 (eGFR ≥ 60 mL/min/1.73 m2), freedom from the primary outcome was similar between the PVI + LVA-ABL and PVI-alone groups (53.1% vs. 55.3%, P = 0.59). In contrast, in patients with CKD G3a-5 (eGFR < 60 mL/min/1.73 m2), freedom from the primary outcome was significantly higher in the PVI + LVA-ABL group than in the PVI-alone group (69.1% vs. 43.3%; P = 0.004).

Conclusion

In patients with renal dysfunction, LVA ablation after PVI reduced AF recurrence after radiofrequency catheter ablation for persistent AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPulmonary VeinsCatheter AblationGlomerular Filtration RateKidneyRenal Insufficiency, ChronicHumansMaleFemaleMiddle AgedRecurrenceAgedProspective StudiesTreatment OutcomeRisk FactorsTime Factors

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationChronic kidney diseaseLeft atrial remodellingRenal function

Autor:innen und Institutionen

  • Cardiovascular Center, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki 660-8511, Japan.
  • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
  • Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital, Osaka, Japan.
  • Division of Cardiology, Osaka General Medical Center, Osaka, Japan.
  • Department of Cardiovascular Medicine, Yao Municipal Hospital, Yao, Japan.
  • Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.

ORCID-Profile: Yasuhiro Matsuda, Masaharu Masuda, Toshiaki Mano, Satoshi Kudo, Mizuki Ochi, Takayuki Ishihara, Kiyonori Nanto, Yosuke Hata, Sho Nakao, Wataru Ariyasu, Akihiro Sunaga, Nobuaki Tanaka, Hitoshi Minamiguchi, Yasuyuki Egami, Takashi Kanda, Masato Okada, Masato Kawasaki, Koji Tanaka, Shungo Hikoso, Tomoharu Dohi, Yohei Sotomi, Yasushi Sakata

Förderung

  • Biosense Webster, Inc.
  • Johnson & Johnson MedTech

Zitieren

APA

Matsuda, Y., Masuda, M., Mano, T., Tsujimura, T., Uematsu, H., Ooka, H., Kudo, S., Ochi, M., Okamoto, S., Ishihara, T., Nanto, K., Hata, Y., Nakao, S., Kusuda, M., Ariyasu, W., Sunaga, A., Tanaka, N., Watanabe, T., Minamiguchi, H., …, & Osaka Cardiovascular Conference (OCVC)-Arrhythmia Investigators (2025). Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial. Europace. https://doi.org/10.1093/europace/euaf205

Vancouver

Matsuda Y, Masuda M, Mano T, Tsujimura T, Uematsu H, Ooka H, et al. Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial. Europace. 2025. doi:10.1093/europace/euaf205

BibTeX
@article{Matsuda2025,
  author = {Matsuda, Yasuhiro and Masuda, Masaharu and Mano, Toshiaki and Tsujimura, Takuya and Uematsu, Hiroyuki and Ooka, Hirotaka and Kudo, Satoshi and Ochi, Mizuki and Okamoto, Shin and Ishihara, Takayuki and Nanto, Kiyonori and Hata, Yosuke and Nakao, Sho and Kusuda, Masaya and Ariyasu, Wataru and Sunaga, Akihiro and Tanaka, Nobuaki and Watanabe, Tetsuya and Minamiguchi, Hitoshi and Egami, Yasuyuki and Oka, Takafumi and Minamisaka, Tomoko and Kanda, Takashi and Okada, Masato and Kawasaki, Masato and Tanaka, Koji and Makino, Nobuhiko and Kida, Hirota and Hikoso, Shungo and Dohi, Tomoharu and Inoue, Koichi and Sotomi, Yohei and Sakata, Yasushi and Osaka Cardiovascular Conference (OCVC)-Arrhythmia Investigators, Osaka Cardiovascular Conference (OCVC)-Arrhythmia Investigators},
  title = {Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf205}
}
Kostenlos starten →